Guggenheim downgraded Cidara Therapeutics (CDTX) to Neutral from Buy without a price target after the company agreed to be acquired by Merck (MRK) in an all-cash transaction for $221.50 per share.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Merck expects over $5B opportunity from Cidara’s flu drug, Reuters reports
- Cidara Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Cidara Therapeutics downgraded to Neutral from Overweight at JPMorgan
- Cidara downgraded to Sector Perform from Outperform at RBC Capital